Kiora Pharmaceuticals Files 8-K on Financials
Ticker: KPHMW · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1372514
| Field | Detail |
|---|---|
| Company | Kiora Pharmaceuticals Inc (KPHMW) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, company-name-change
Related Tickers: KPRX
TL;DR
Kiora Pharma dropped an 8-K detailing financials - check it out.
AI Summary
Kiora Pharmaceuticals, Inc. filed an 8-K on March 25, 2024, reporting on its financial condition and results of operations. The filing also includes financial statements and exhibits. The company was formerly known as Eyegate Pharmaceuticals Inc. before changing its name on August 11, 2006.
Why It Matters
This 8-K filing provides investors with an update on Kiora Pharmaceuticals' financial health and operational performance, which is crucial for evaluating the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- KIORA PHARMACEUTICALS INC (company) — Registrant
- Eyegate Pharmaceuticals Inc (company) — Former company name
- March 25, 2024 (date) — Date of report
- August 11, 2006 (date) — Date of name change
FAQ
What is the primary purpose of this Form 8-K filing for Kiora Pharmaceuticals, Inc.?
The primary purpose of this Form 8-K filing is to report on the Results of Operations and Financial Condition of Kiora Pharmaceuticals, Inc., and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 25, 2024.
What was Kiora Pharmaceuticals, Inc. formerly known as?
Kiora Pharmaceuticals, Inc. was formerly known as EYEGATE PHARMACEUTICALS INC.
On what date did the company change its name from Eyegate Pharmaceuticals Inc.?
The company changed its name from Eyegate Pharmaceuticals Inc. on August 11, 2006.
What is the business address and phone number listed for Kiora Pharmaceuticals, Inc.?
The business address is 332 Encinitas Blvd., Suite 102, Encinitas, CA 92024, and the telephone number is (858) 224-9600.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-25 07:03:36
Key Financial Figures
- $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che
Filing Documents
- kprx-20240325.htm (8-K) — 25KB
- ex991-pressreleasedecember.htm (EX-99.1) — 24KB
- picture1.jpg (GRAPHIC) — 31KB
- picture2.jpg (GRAPHIC) — 19KB
- 0001372514-24-000027.txt ( ) — 250KB
- kprx-20240325.xsd (EX-101.SCH) — 2KB
- kprx-20240325_lab.xml (EX-101.LAB) — 22KB
- kprx-20240325_pre.xml (EX-101.PRE) — 13KB
- kprx-20240325_htm.xml (XML) — 3KB
02. Results of Operations and Financial Conditions
Item 2.02. Results of Operations and Financial Conditions. On March 25, 2024, Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Press Release of Kiora Pharmaceuticals, Inc., dated as of March 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Executive Vice President of Finance (Principal financial and accounting officer) Date: March 25, 2024